Items tagged with Treatment
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows (post)
HIV, hepatitis B and C and TB can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported at the 9th International AIDS Society Conference on HIV Science in Paris.
US govt supports introduction of new TB drug to PNG (post)
The United States Agency for International Development (USAID) is working with partner organisations to introduce a new drug into Papua New Guinea called bedaquiline, the first new drug for tuberculosis in over 45 years.
Treatment initiation among persons diagnosed with drug-resistant TB in Johannesburg, South Africa (post)
Abstract
Mylan gets DCGI approval to market anti-TB drug delamanid (post)
Mylan’s TB drug delamanid will be limited to those patients who have stopped responding to most of first and second line of treatment
J&J partners with CSIR-IMTECH on TB treatments (post)
The Indian subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ) announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new tuberculosis (TB) treatments.
TB drug may work better than others in its class (post)
Computer simulations suggest moxifloxacin outperforms two other drugs when doses are missed
Otsuka and Mylan announce license agreement to commercialize delamanid (Deltyba™) for MDR-TB in high-burden countries (post)
TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries. Delamanid was discovered and developed, and is currently marketed by Otsuka under the brand name Deltyba™.
NIH funds SLU research of possible treatment for drug-resistant TB (post)
Saint Louis University is leading a multi-national clinical trial of what could become a regimen for drug resistant tuberculosis (TB) that does not require injectable medications. The project is funded by a $6.4 million task order from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Six-month response to delamanid treatment in MDR-TB patients (post)
Abstract
Off-label use of bedaquiline in children and adolescents with multidrug-resistant TB (post)
Abstract
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
Page 33 of 108 · Total posts: 0
←First 32 33 34 Last→